Phosphodiesterases
==================

Introduction
------------

The cyclic nucleotides, cAMP and cGMP are second messengers that regulate signal transduction in various biological systems. They respond to extracellular signals (neurotransmitters, hormones, olfactive and luminous signals) and activate intracellular targets such as ion channels, kinases, and transcription factors that trigger the cellular response to the message. The extracellular signal is thus transferred by the cyclic nucleotides to one of the effector proteins, the most important of these are protein kinase A (PKA) and protein kinase G (PKG) that, in turn, phosphorylate other enzymes or transcription factors ([Figure 1](#fig1){ref-type="fig"}).

![Cyclic nucleotide signal. The extracellular signal (neurotransmitters, hormones, olfactive and luminous signals) is transferred by the cyclic nucleotides cAMP and cGMP to one of the effector proteins, the most important of these are ion channels, protein kinase A (PKA) and protein kinase G (PKG). The kinases, in turn, phosphorylate other enzymes or transcription factors such as CREB in the nucleus. Cyclic nucleotides levels are maintained through a balance between production, carried out by adenyl cyclase (AC) and guanylil cyclase (GC) from ATP and GTP, respectively, and destruction, carried out by phosphodiesterases (PDEs) that lead to the formation of the inactive forms 5'AMP and 5'GMP.](ndt0402-371-01){#fig1}

The levels of cAMP and cGMP are maintained thanks to a balance between production, carried out by adenyl cyclase (AC) and guanylyl cyclase (GC), and destruction, carried out by phosphodiesterases (PDEs) ([Figure 1](#fig1){ref-type="fig"}). PDEs regulate the nucleotide signal both in amplitude and duration (spatial and temporal regulation) and modulate the "cross talk" between various second messengers. For example many effects of Ca^2+^ on cAMP and cGMP are mediated by the activation of the Ca^2+^-Calmodulin (Ca^2+^-CaM) dependent phosphorylation of PDEs ([@b218]).

Over the last few years there has been an increasing number of studies on PDEs. This is also thanks to the potential use of these enzymes as targets of drugs that can regulate the levels of cyclic nucleotides and the various physiological functions connected to them. The recognition of the therapeutic potential of PDEs stems from the ubiquitous nature of the second messengers on which these enzymes act. Notwithstanding the great potential of these inhibitors, the only pathologies currently treated with PDE inhibitors are erectile dysfunction and, more recently, pulmonary hypertension. This is due to the complexity of the PDE family and the selectivity of the inhibitors used. Various studies are now focusing on the role of PDEs in the CNS and on the potential use of PDE inhibitors for nervous system disorders. This can be explained by the presence of PDEs in various regions of the CNS ([@b10]; [@b210]; [@b70]; [@b213]; [@b116]; [@b188]; [@b139]; [@b177]; [@b259]; [@b129]; [@b50]; [@b207]; [@b6]; [@b65]; [@b226]; [@b241]; [@b102]; [@b120]; [@b164]; [@b176]; [@b189]) and to the fact that cAMP and cGMP have been recognized as secondary messengers of various neuronal phenomena such as synaptic plasticity ([@b62]; [@b115]; [@b263]; [@b63]; [@b222]; [@b208]; [@b270]; [@b269]; [@b8]; [@b255]; [@b220]; [@b143]; [@b187]; [@b262]; [@b30], [@b31]; [@b72]; [@b246]; [@b247]; [@b15]; [@b75]; [@b145]; [@b137]; [@b254]).

Background
----------

The activity of PDEs was described for the first time in 1886, when Dr Henry Hyde Salter noted that caffeine had bronchodilator properties ([@b32]). In 1958, Sutherland and Rall first identified the nucleotide cAMP in liver extracts as a second messenger and suggested that it could mediate several cellular effects of neurotransmitters and hormones ([@b225]). The existence of an enzymatic activity able to catalyze the degradation of this molecule was used as one of the initial processes supporting the evidence that cAMP is a relevant molecule from the physiological point of view ([@b225]). Indeed, Sutherland and colleagues discovered that glucagon and catecholamines act in the liver by increasing the concentrations of cAMP and that the effect of caffeine on glucagon involved the inhibition of cAMP-dependent PDEs ([@b23]; [@b185]; [@b40]; [@b73]). In 1970 PDEs were differentiated in rat and bovine tissue and it was demonstrated that the specificity of the reaction was due to the hydrolysis of the cAMP and cGMP phosphoester bond ([@b18]). With the development of radionucleotides it was possible to measure PDE activity at the substrate level at nearly physiological concentrations. From then various PDEs have been isolated, purified and characterized.

Classification
--------------

The superfamily of PDEs is divided into three principle classes I, II and III, having different sequences. Class I includes all the mammal PDEs ([@b84]) as well as Drosophila ([@b47]), *Caenorhabditis* ([@b122]), and yeast ([@b200], [@b233]). These enzymes are produced by different genes ([@b17]; [@b76]) and show high affinity for the cGMP and /or cAMP molecule. Class II includes enzymes from fungi such as *Saccharomyces cerevisae* ([@b163]), *Dictyostelium discoideum* ([@b128]), *Schizosaccharomyzes pombe* ([@b60]), *Candida albicans* ([@b104]) and one from bacteria, *Vibrio fischeri* ([@b66]). PDE class II shares a conserved motif containing three histidine residues that may be part of a metal ion binding site such as Zn^2+^ for *Vibrio fischeri* ([@b41]). Class III includes only enzymes from prokaryotes such as *Escherichia coli* ([@b190]). Given that the catalytic site of PDE class III is comparable to the purple acid phosphatases, these enzymes could be considered as members of a large family of structurally related dimetallophosphoesterases ([@b190]).

Twenty-one classes of genes and diverse spliced transcriptional variants for the PDE class I of humans, rats and mice have been identified. They have been classified into 11 families based on particular subcellular distributions, structural similarities, mechanisms of regulation, amino acid sequences, proteic domains and enzymatic properties among which are specificity for the substrate, kinetic proprieties, and sensitivity to endogenous regulators and inhibitors.

Some PDEs are highly specific for cAMP (PDE4, PDE7, PDE8); others are highly specific for cGMP (PDE5, PDE6, PDE9), and some have mixed specificity (PDE1, PDE2, PDE3, PDE10). The nomenclature assigns an Arabic number to each family with an individual gene expressed by a letter and every spliced variant of the gene is identified by a number (ie, PDE5A1).

Structure and mechanism of action
---------------------------------

All PDEs are dimeric though the importance of this structure is not well known. Each has a core of 270 amino acids with a high degree of conservation (25%--35%) among the various families that is localized at the C-term and contains the catalytic domain of the enzyme. Within each family, the sequence of the catalytic domain is highly conserved (\>75%). This makes the identification of the inhibitors of the active site possible and distinguishable between the different families, with the exception of the very high homology between PDE5 and PDE11 that makes, for example, some inhibitors of PDE5 such as tadalafil also active against PDE11 ([@b248]).

Most PDEs have a regulatory domain at the N-term that varies among the families and provides the sites for dimerization, phosphorylation and modulatory bonds such as Ca^2+^-CaM and cGMP. For example, PDE1 contains a Ca^2+^/CaM-binding domain that activates the enzyme. About half of the genetic families have a GAF domain (PDE2, PDE5, PDE6, PDE10, PDE11) that mediates the allosteric regulation of the bond with cGMP. The other PDEs belong to NON-GAF-PDEs. It is believed that some PDEs also possess an auto-inhibitory domain in the structure of the enzyme that is detected by some PDE activators ([@b113]; [@b218]).

PDEs are ubiquitously distributed and most of them have been found in CNS (for a review see [@b21]). The cGMP-hydrolysing PDE2, PDE5, and PDE9 and the cAMP-hydrolysing PDE4 and PDE7 are located in the hippocampus where they are likely to be involved in memory and/or long-term potentiation (LTP; [@b19]; [@b13]; [@b103]; [@b156]; [@b26]; [@b91]; [@b242]; [@b256]; [@b189]). PDE6 has also been found in the hippocampus, although it does not affect synaptic transmission or synaptic plasticity ([@b125]).

PDEs hydrolyze the phosphodiesteric bond of cyclic nucleotides between the atoms of phosphorus and oxygen in position 3' with the inversion of the phosphorus atom configuration ([@b39]; [@b90]) and the consequent formation of adenosin monophosphate (AMP) and guanosin monophosphate (GMP), which are recycled as substrates for the formation of ATP and GTP.

PDEs are regulated by means of 3 principal mechanisms: i) Availability of the substrate, such as the stimulation of PDE activity after the increase of the levels of cyclic nucleotides or after alteration of the ratio of hydrolysis between one nucleotide and another; ii) Regulation of the intracellular signal by extracellular signals (ie, phosphorylation); iii) Feedback regulation ([@b53]).

Phosphodiesterase 5
===================

Characteristics
---------------

PDE5 is a cGMP-specific enzyme that hydrolyzes cGMP. The cyclic nucleotid plays a fundamental role in signal translation. It stimulates the relaxation of smooth muscle, the degranulation of neutrophils, inhibits platelet aggregation and initiates translation of the visual signal ([@b85]; [@b101]; [@b135]; [@b86]; [@b158]; [@b140]; [@b53]). cGMP is one of the targets for the action of nitric oxide (NO), a particular neurotransmitter, which is the main subject of this review.

As mentioned above, the tissue levels of cGMP depend on the balance between the activity of GC that catalyzes the formation of cGMP from GTP, and from PDEs that catalyze the breakdown of cGMP into GMP.

PDE5 was purified in 1980 by Francis and colleagues from rat lungs ([@b83]; [@b81]) and cloned in 1993 by McAllister-Lucas ([@b153]). Two spliced variants have been recognized ([@b142]; [@b260]). At first it was believed that PDE5 was part of PDE6 (PDE of the photoreceptors) given its notable similarity. However, considering that the sequence identity is less than 60% ([@b153]), PDE5 was subsequently classified as a separate family.

The tissue distribution of PDE5 generally coincides with that of PKG, probably because both enzymes are the principal intracellular receptors of cGMP. Moreover, PKG is an excellent in vitro catalyst for the phosphorylation of PDE5 ([@b232]). PDE5 has a typical cytosolic localization with high levels in smooth muscle, platelets, kidney and in some zones of the CNS ([@b82]; [@b121]; [@b242]; [@b64]; [@b155]).

The NO/cGMP pathway
-------------------

To understand the function of PDEs it is necessary to know the pathway by which they act. cGMP is produced by the GC enzyme, an NO target. NO is a molecule that has been widely studied since 1800, when the potential therapeutic role of nitroglycerin with its vasodilatatory effect was discovered for the treatment of *angina pectoris* ([@b36]). It was later discovered that the effect of NO was mediated through cGMP synthesis, which activated vascular reactions. NO was identified in the nervous system in 1988 as a molecule that was able to mediate the increase of cGMP after the activation of the glutamatergic receptor N-methyl-D-aspartate (NMDA) ([@b87]).

Over the last few years the function of NO as a neurotransmitter has been studied ([@b183]). A particular characteristic is its capacity to function as a retrograde neurotransmitter able to transfer information from the post- to the pre-synaptic terminal. This completely revolutionized the concept of synaptic transmission and neuronal communication.

The formation of NO is catalyzed by the NO synthase enzyme (NOS) of which different variants exist: i) the Ca^2+^-dependent constitutive form (c-NOS), consisting of the endothelial form (e-NOS) or type III and the neuronal form (n-NOS) or type I, present in the endothelium, and in glial and neuronal cells that produce NO in physiological conditions; ii) the Ca^2+^-independent inducible form (i-NOS) or type II, present in macrophages, hepatocytes, smooth muscle, glia and endothelium that produces NO following immunological stimuli (ie, interferon γ, tumor necrosis factor α, LPS).

The biological receptor of NO is GC, a ubiquitous enzyme that, once activated, catalyzes the formation of cGMP. cGMP has various targets among which are cGMP-dependent channels, PKG, and PDEs. PKG are mediators of signal translation ([@b140]). PKGI, composed of the α and β subunits, is ubiquitous; the monomeric PKGII is expressed in various tissues such as the lung, kidney, testicle and brain. cGMP can also activate the cAMP pathway acting on the cAMP binding site and PKA ([@b238]).

Structure and function of PDE5
------------------------------

The human gene for PDE5 has been mapped in the 4q26 chromosome, which contains 24 exons that occupy approximately 100 k bases ([@b260]). The enzyme PDE5 is an active homodimer, with an MW of \~ 3000 kd ([Figure 2](#fig2){ref-type="fig"}). Each monomer contains a catalytic domain in the C-term with 2 binding sites for Zn^2+^. These are involved in the process of catalysis and it is believed that the catalytic activity of PDE 4, 5 and 6 is sustained by submicromolar concentrations of Zn^2+^ ([@b80]; [@b174]; [@b99]). In the C-term catalytic domain there is an allosteric binding site for cGMP and in the N-term regulatory domain there are two allosteric binding sites called GAF a and b domains ([@b152]). It is likely that GAFa is responsible for the allosteric binding of cGMP ([@b136]; [@b274]). Both the allosteric and catalytic sites are highly specific for cGMP. The catalytic domain has high affinity for cGMP (Km \~ 1--5 μM, compared with Km \~ 300 μm of cAMP). Binding of cGMP to the allosteric site is necessary for the specific phosphorylation of Ser-92 by PKG. The bond not only activates the catalytic function but increases the binding affinity for cGMP ([@b54]; [@b79]; [@b274]). The two allosteric sites homologous for cGMP (a and b) are kinetically distinct. Both sites need to bind to cGMP for PDE activation. The increased interaction of cGMP with the catalytic site increases the binding of cGMP in the allosteric site thus increasing the phosphorylation of the enzyme promoting a further increase of cGMP cleavage.

![Schematic representation of PDE5 structure. PDE5 is a homodimer containing, in each monomer, a C-term catalytic domain and an N-term regulatory domain. The catalytic domain contains 2 Zn^2+^-binding sites (A and B) and an allosteric binding site for cGMP. The regulatory domain contains two allosteric binding sites called GAF a and b, domains responsible for the allosteric binding of cGMP. The occupation of the allosteric site by cGMP is necessary for the specific phosphorylation of Ser-92 by PKG.](ndt0402-371-02){#fig2}

There are three isoforms of PDE5 (PDE5A1-PDE5A3) which are distinguished based on their N-term sequence. PDE5A1 and PDE5A2 are ubiquitous, but PDE5A3 is specific to smooth muscle ([@b134]). A single PDE5A gene encodes for the 3 isoforms and the initial three exons (A1-A3-A2) encode the isoform-specific sequences. The promoters are responsive to cGMP or cAMP stimulation, and several studies have demonstrated regulation of PDE5 expression possibly through these promoters (Lin et al 2006). The potential role of different PDE5A promoters in the effect of PDE5 inhibitors is currently being investigated ([@b134]). Moreover, the study of the 3 isoforms may be relevant for future drug development as our knowledge of PDE structure-function relations increases.

The principal functions of PDE5 consist of modulating hemodynamics affecting the contracted state of vessel cells by regulating the phasic nature of smooth muscle physiology ([@b107]; [@b196]; [@b182]; [@b44]). PDE5 exerts its action in all smooth muscle districts modulating, other then the tone of blood vessels, the contractile state of organs such as the penis, uterus, and intestines. However, its function has been mainly studied in the corpora cavernosa and in the pulmonary system given the therapeutical implication of the use of PDE5 inhibitors aimed at provoking a relaxation of these organs to alleviate erectile dysfunction and pulmonary hypertension ([@b273]; [@b52]; [@b249]; [@b133]; [@b234]; [@b131]). PDE5 plays also a key role in the peripheral vessel system by regulating systemic blood pressure. Moreover, PDE5 is involved in the regulation of the response to the atrial natriuretic peptide (ANF) ([@b250]) and it might regulate Na^+^ retention ([@b89]).

[Figure 3](#fig3){ref-type="fig"} shows the effects exerted by cGMP in some target organs and the possible therapeutical application of PDE5 inhibitors leading to an increase of cGMP.

![cGMP functions and possible therapeutic use of PDE5 inhibitors. PDE5 inhibitors block the degradation of cGMP (bottom panel) leading to an increase of the level of cGMP that can exert its action on several target organs. On the right side, both the approved and possible (question mark) therapeutical applications of PDE5 inhibitors in humans.](ndt0402-371-03){#fig3}

PDE5 Inhibitors
===============

Sildenafil and other PDE5 inhibitors
------------------------------------

For many years, nonselective PDE5 inhibitors such as caffeine, theophylline and IBMX have been used to investigate the physiological effects of cyclic nucleotides. A more selective inhibitor called sildenafil has now attracted the attention of many researchers. Sildenafil is the active agent of the widely diffused drug Viagra used for erectile dysfunction (ED).

Sildenafil, initially synthesized with the aim of treating arterial hypertension and *angina pectoris*, was the first drug approved by the USA Food and Drug Administration for the treatment of ED ([@b74]). To date it is the principle treatment for ED given its risk-benefit ratio. Sildenafil, with the commercial name of Revatio (Pfizer), was also approved for the therapy of hypertension of the pulmonary artery in June 2005. Various studies indicate that sildenafil can offer new strategies for the treatment of other pathologies such as multiple sclerosis (MS), pain, and memory loss ([@b239]).

Thanks to these discoveries, thousands of compounds have been synthesized and screened against PDE5. Reported PDE5 inhibitors can be divided into the following classes: 1) cGMP-based, represented by sildenafil (Viagra) and vardenafil (Levitra) (Pfizer, Bayer, Sheering-Plough), 2) β-carboline -- derived, represented by tadalafil (Cialis) (Lilly, Johnson&Johnson \[J&J\], 3) quinazoline and isoquinolinone derivatives (Bristol-Myers-Squibb \[BMS\], Japan), and 4) phthalazine derivatives (BMS, Japan).

Among these vardenafil and tadalafil are considered the most potent inhibitors ([@b127]). Vardenafil is a new drug used for erectile dysfunction. It has an IC50 of 0.7 nM for PDE5 with respect to other PDEs (PDE1: 180 nm; PDE2, 3, 4 \>1 μm; PDE6: 11 nm) ([@b197]). The inhibitory potential of vardenafil towards PDE5 is 5 times greater than sildenafil.

Differently than sildenafil and vardenafil, which are cGMP-based inhibitors, tadalafil is a β-carboline-derived drug with no effect on PDE1 (selectivity ratio \>2000) and on PDE6 (selectivity ratio 1000), and an IC50 against PDE5 of 5.0 nM ([@b57]). Tadalafil is a second generation oral drug. It acts quickly and its effects last longer than sildenafil ([@b77]).

Sildenafil, vardenafil, and tadalafil are rapidly absorbed in the gastrointestinal tract at the level of the small intestine. The half life of sildenafil and vardenafil is \~ 3--4 h whereas tadalafil has a half-life of \~ 18 h ([@b127]; [@b77]). They are all metabolized by means of the p450 cytochrome system and also eliminated by this system at the hepatic level.

The possible use of these drugs in the CNS is also related to their ability to cross the blood -- brain barrier (BBB). Sildenafil is reported to clearly cross the BBB ([@b74]). Evidence for the ability of vardenafil to cross the BBB is indirect ([@b179]), and tadalafil is unlikely to cross it (personal communication from V. florio at Icos).

These drugs can have side effects such as headaches, facial flushing, nasal congestion, and dyspepsia. These effects are, however, transitory and disappear with the suspension of the drug. Moreover, both sildenafil and vardenafil can act on PDE6, which is present in the retina, thus high doses can cause vision problems. Tadalafil, moreover, can inhibit PDE11. These drugs are not suitable for cardiopathic subjects, due to the possible vasodilatatory effects, and hypotensives, as well as in subjects who suffer from orthostatic hypotension, aortic stenosis, obstructive hypertrophic cardiomyopathy, and retinitis pigmentosa ([@b127]).

PDE5 inhibitors and neurogenesis
--------------------------------

Neurogenesis is the production of new neurons, and it is a process that is active mostly during prenatal development, though new neurons are also produced during adult life in some areas of the brain such as the subventricular zone (SVZ) and the subgranular zone (SGZ) of the dentate gyrus of the hippocampus of mammals, including humans, and other species ([@b3]; [@b71]; [@b93]; [@b268]; [@b229]; [@b118]). The functional significance of adult neurogenesis is just beginning to be understood and there is considerable disagreement in literature. There is evidence showing that adult neurogenesis in the hippocampus plays a role in synaptic plasticity ([@b198]; [@b34], [@b35]; [@b202]) and memory ([@b211], [@b212]; [@b216]; [@b24]; [@b35]; [@b67]; [@b69]; [@b240]). Higher levels of neurogenesis resulting from an enriched environment are reported to correspond to better acquisition of the Morris Water Maze task in mice (Kempermann et al 2002) and new neurons have been shown to be necessary for consolidation of memory after water maze training ([@b216]). It seems that new neurons can increase mnemonic capacity ([@b20]), reducing the interference between newly formed memories ([@b253]), and adding spatial-temporal details to the new memory ([@b2]).

It also appears that neurogenesis plays a key role in the regulation of stress and that this is in turn linked to the integrity of the hippocampus. Some studies have, in fact, demonstrated that the positive activity of some anti-depressants is linked to the stimulation of hippocampal neurogenesis ([@b146]; [@b148]) and that inhibition of hippocampal neurogenesis induced by radiation blocks the effects of anti-depressants ([@b199]). Other studies have shown that memory is correlated with mood disorders, particularly with depression, and that mood is regulated by the phenomena of neurogenesis and synaptic plasticity ([@b43]; [@b167]).

Hippocampal neurogenesis is controlled by various factors such as physical exercise, stress, sleep, environmental conditions, hormones (testosterone), neurotransmitters (serotonin) and intrinsic growth factors ([@b42]; Lledo et al 2006), which can affect different stages of the neurogenetic process. Neurogenesis is also stimulated by hippocampal or cortical damage ([@b55]; Blumcke et al 2001; [@b111]; [@b112]) and could be modified by pathologies such as Alzheimer's disease ([@b126]).

It is interesting to note that some studies have shown that sildenafil plays a role in potentiating neurogenesis through the increase of cGMP levels. NO influenced sensory-induced neurogenesis ([@b45]) and prenatal development of the brain through cGMP ([@b48]). Furthermore, neuronal growth decreases with age in parallel with the reduction of cGMP levels ([@b227]). Several studies have demonstrated that sildenafil can be used to stimulate neurogenesis after stroke. In rats, Sildenafil induces neurogenesis, reduces neurological deficit and promotes the functional recovery after stroke and focal cerebral ischemia ([@b266]; [@b267]). Tadalafil has also been used to improve neurogenesis in an embolic model of stroke in rats ([@b265]). Thus, it is possible that in the future PDE5 inhibitors might be used to stimulate neuronal function and improve neurogenesis in older subjects or in patients affected by AD and other disorders characterized by hippocampal memory impairment.

PDE5 inhibitors and memory
--------------------------

### Role of NO/cGMP in synaptic plasticity and memory

Synaptic plasticity is an active phenomenon consisting of all the structural and/or neuronal functional modifications that allow adaptation to new situations ([@b100]). It is thought to be at the bases of learning and memory and occurs in various cerebral structures such as the hippocampus, the cerebral cortex and the cerebellum.

The most studied form of synaptic plasticity is long-term potentiation (LTP) occurring at the excitatory synapses of the hippocampus and consisting of an increase in the amplitude of the post-synaptic excitatory potentials (EPSPs) after high frequency stimulation (tetanus) of the afferent fibers. LTP can be detected in various areas of the hippocampus but it is mostly observed in the CA1 pyramidal cells and pre-synaptic fibers forming the Schaffer collateral, which is implicated in learning and memory. Many studies support the hypothesis that LTP underlies memory ([@b132]; [@b159]; [@b192]; [@b61]; [@b94]; [@b37]; [@b144]), although the complex mechanisms involved in memory have not yet been fully clarified. Various studies have shown that LTP and memory depend on a cellular cascade stimulated by an increase of the intracellular concentrations of cAMP with the subsequent activation of PKA and the phosphorylation of the cAMP responsive element binding protein (CREB) ([@b33]; [@b105]; [@b261]; [@b191]; [@b1]; [@b157]; [@b160]; [@b209]; [@b228]; [@b166]; [@b221]; [@b92]). Besides cAMP, a fundamental role is played by the cGMP/PKG/CREB pathway that seems to act in parallel with the cAMP/PKA/CREB pathway.

Studying the role of the cGMP pathway in memory stems from the crucial need to identify pre- and post-synaptic mechanisms in LTP. In the early 1990s it was suggested that the induction of LTP involves a retrograde message released at the post-synaptic level and acting at the pre-synaptic level ([@b28]; [@b165]; [@b204]). Various studies have shown that NO is necessary for LTP: i) inhibitors of NOS block LTP and this inhibition is corrected administering precursors of NO ([@b204]; [@b95]; [@b97]; [@b28], [@b27]; [@b29]); ii) knock-out mice for nNOS and eNOS show LTP impairment ([@b217]); iii) exogenous application of NO induces plasticity ([@b272]; [@b9]; [@b30]); and iv) NO is able to stimulate the release of spontaneous pre-synaptic neurotransmitter release in cell cultures ([@b165]).

Given that cGMP is a downstream effector of NO, the involvement of the cGMP/PKG/CREB pathway has also been investigated. These studies showed that: i) inhibitors of GC block the induction of LTP ([@b97]; [@b271]; [@b5]); ii) analogs of cGMP produce potentiation despite the block of upstream NMDA receptors and NO release ([@b97]; [@b8]); and iii) inhibitors of GC and of PKG block LTP ([@b8], [@b7]).

Behavioral studies have also shown that NO is involved in the phenomenon of learning and memory ([@b98]; [@b224]). [@b28] demonstrated that the inhibition of endogenous NO impaired spatial learning tested with a radial arm maze and olfactive memory, but had no effect on shock-avoidance learning. Studies on nNOS knockout mice or by using inhibitors of NOS have shown an impairment of spatial performance with the Morris water maze (MWM) and object recognition memory in rats ([@b46]; [@b180]; [@b275]; [@b119]; [@b123]). Moreover, the block of spatial memory obtained by blocking the NMDA receptors could be restored using NO donors or cGMP analogs ([@b258]). The effect of NO on behavior is mediated by the cGMP/PKG pathway. In fact, passive avoidance learning in rats increased cGMP levels in the hippocampus and the administration of 8-Br-cGMP, a cGMP analog ([@b22]), or zaprinast, a selective cGMP PDE inhibitor ([@b180]), improved memory. On the other hand, the post-training inhibition of GC or PKG activity blocked memory formation ([@b22]).

### Role of NO/cGMP in Alzheimer's disease

One of the most widespread and invalidating pathologies that causes a deficit of cognitive functions is Alzheimer's disease (AD). AD is a progressive neurodegenerative disorder characterized by loss of memory and behavioral problems leading to dementia. The advanced stages of the pathology are characterized by the presence of senile plaques at the cerebral level, principally made up of beta-amyloid peptide (Aβ) and neurofibrillary tangles ([@b205]). However, the early symptoms, which consist in the loss of memory, also occur without signs of cerebral alterations and are probably due to a synaptic dysfunction caused by Aβ ([@b56]; [@b130]; [@b106]; [@b49]; [@b243]; [@b244]). It appears, in fact, that Aβ causes a deficit at the excitatory neurotransmission level causing a synaptic dysfunction that precedes the structural alteration with a loss of neurons ([@b206]).

Aβ has various targets that have been well studied and that could identify new therapeutic approaches ([@b151]). Various studies suggest that the NO/cGMP pathway can be involved in the pathogenesis of AD. These studies have indicated a dual role for NO: neuroprotective and neurotoxic. Some authors have shown that by acting on the NO/cGMP pathway with NO donors, cGMP analogs, or PDE inhibitors, it is possible to obtain an improvement of the Aβ-induced damage both at the level of the CNS and the vascular system ([@b154]; [@b150]; [@b169]; [@b237]; [@b252]). In particular, inhibition of PDEs appears to block the vasoconstriction and inflammation of the microglia induced by Aβ ([@b168]). Given that the NO/cGMP/PKG pathway is involved in LTP, a phenomenon that is altered in the early phases of the pathology in transgenic mouse models ([@b236]), it has been demonstrated that this pathway has a protective role with regards to Aβ-induced LTP impairment ([@b184]). Moreover, an enhancement of this pathway has been associated with a restoration of the phosphorylation of CREB ([@b184]), a transcription factor linked to memory ([@b33]; [@b261]; [@b141]). The potential neurotoxic role of NO has been focused on in many studies showing that activation of iNOS in microglia in response to Aβ is involved in AD pathogenesis ([@b170]; [@b235]; [@b96]; [@b257]). A unifying hypothesis that combines studies on protective and toxic roles of NO is that the two constitutive NOS, n-NOS and e-NOS, have a potential neuroprotective role while i-NOS mediates the oxidative stress induced by NO.

### Use of PDE5 inhibitors as a memory enhancer

It has been shown that the PDE5 inhibitor sildenafil influences long-term memory retention in mice by modulating mechanisms involved in memory storage ([@b14]). Moreover, the inhibition of PDE5 improves object memory ([@b181], [@b179]; [@b195]) and counteracts spatial learning impairment induced by NOS inhibition ([@b59], [@b58]) and by blockade of cholinergic muscarinic receptors in rats ([@b59]). Other studies have shown that sildenafil produces a dose-dependent improvement of memory in mice tested with elevated plus maze ([@b214]). Sildenafil effects have also been tested on selective auditory attention and verbal recognition memory in humans ([@b203]). Despite the fact that no differences in behavioural patterns were found, sildenafil enhanced the ability to focus attention on streams of auditory stimuli, as revealed by an improvement of the typical ERP components.

As mentioned above, Aβ has been implicated as a key molecule in AD pathogenesis. Several studies have tried to clarify the second messenger pathway(s) by which Aβ affects synaptic plasticity and memory. The cAMP/PKA/CREB pathway has been found to be involved in Aβ-induced LTP impairment ([@b243]; [@b91]). Rolipram, a PDE4 inhibitor increasing cAMP levels, reversed the inhibition of PKA activity and CREB phosphorylation most probably by favoring the dissociation of regulatory and catalytic subunits of PKA and the restoration of PKA activity ([@b243]). Moreover, treatment with Rolipram re-estabilished LTP and contextual learning in animal models of AD (APP/PS1 mice) and, most importantly, this beneficial effect could be extended beyond the duration of the administration ([@b91]). Aβ has also been found to downregulate the NO pathway leading to a reduction in CREB phosphorylation through reduced activation of PKG ([@b184]). Recent studies have shown that nitrates might counteract microglia activation and Aβ deposits ([@b237]; [@b110]) and NO-mimetic molecules may reverse cognitive impairment in AD ([@b231], 2005). Thus, enhancers of the cAMP/PKA/CREB or NO/cGMP/PKG/CREB pathways might represent novel classes of compounds that could effectively counteract disease progression by acting at the downstream level of Aβ production. PDE inhibitors have been proposed to be employed as memory enhancers ([@b25]; [@b193]; [@b194]). With regard to the use of these inhibitors, it is noteworthy that the development of PDE4 inhibitors as CNS drugs has been a very difficult endeavour because of undesirable side effects, or lack of efficacy at the doses used to avoid side effects. For instance, the PDE4 inhibitor Rolipram, used for its anti-depressant and anti-inflammatory effects, causes a number of side-effects (especially nausea and headache), which have limited its therapeutic use ([@b219]). Thus, it is possible that inhibiting PDE5s might be an alternative and perhaps more suitable strategy than inhibiting PDE4s to develop a drug targeted to CNS and memory.

Based on these findings, and considering that the current therapy for AD (acetylcholinesterase inhibitors, NMDA antagonists, drugs that reduce Aβ levels or its oligomerization, formation of neurofibrils, oxidative stress, and inflammation of the microglia; [@b201]; [@b161]; [@b245]) has a limited efficacy, our group is currently studying the possibility of using PDE5 inhibitors in AD. Acting on a specific Aβ target such as the NO/cGMP/PKG pathway through PDE5 inhibitors could represent a useful therapeutic approach to block the disease at an early stage, before structural damage occurs. Moreover, it appears that Aβ, other than accumulating in the brain, is also present in the blood stream where it can cause phenomena of vasoconstriction that lead to arterial hypertension ([@b16]; [@b5]; [@b114]; [@b223]; [@b179]; [@b215]), often associated with AD ([@b171]; [@b88]; [@b178]). It would thus be interesting to use PDE5 inhibitors to contrast both the neurological and vascular symptoms associated with this pathology.

Use of PDE5 inhibitors in other nervous system diseases
-------------------------------------------------------

All PDEs are expressed at the level of the nervous system suggesting that they could be targeted by some drugs used for pathologies of the nervous system. Sildenafil has been proposed for pain therapy both in humans and animals ([@b12]; [@b108]; [@b172]; [@b4]). Chronic neuropathic pain, often associated with nervous system diseases, is very difficult to treat therapeutically ([@b175]). Opioids have been found ineffective and the possible use of a low dose of ketamine produces a transient amelioration ([@b68]; [@b149]; [@b251]; Pedersen et al 2006), but can also give memory impairment and psychotic symptoms ([@b124]; [@b147]). Recent studies have shown that sildenafil can be used for the treatment of pain in animal models ([@b12]; [@b108]; [@b172]; [@b4]) because of the peripheral accumulation of cGMP that it is likely to have an anti-nociceptive effect ([@b109]). A further interesting application would be the treatment of diabetic neuropathy in which alteration in nNOS seems to be a key factor ([@b172]).

Sildenafil has also been shown to have a potential application in MS, a chronic inflammatory CNS disease characterized by demyelinization of nerve cells that leads to severe psychomotor disability. There is no definitive therapy for MS but the different approaches (interferon, glatiramer acetate, novantrone, natalizumab, corticosteroids, and miorelaxants) aim to cure the symptoms and the progression of the pathology. Given its role in neuroprotection and neurogenesis (see above), sildenafil might have a potential application in patients with MS. Moreover, it has been demonstrated that sildenafil can be useful to successfully treat ED in MS ([@b78]) and other neurological disorders such as spina bifida and Parkinson's disease ([@b162]).

Conclusions
===========

This review summarizes the effect of PDE5 in physiological processes and, in particular, on synaptic plasticity and memory. Given the widespread distribution of PDE5, the use of selective PDE5 inhibitors such as sildenafil, vardenafil, and tadalafil has been widely investigated. The use of PDE5 inhibitors is now approved by the FDA for the therapy of ED and pulmonary hypertension, however, many other diseases might take advantage of these drugs. Among these, particular attention should be given to CNS diseases characterized by cognitive impairment such as AD. Moreover, given the role of sildenafil in neurogenesis, CNS diseases such as mood disorders, MS and stroke might be approached with PDE5 inhibitors. The role of PDE5 on nociception should be another field of further investigation.
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